DEF: Envoy Medical Seeks Stockholder Approval for Reverse Stock Split

Envoy Medical is holding a special meeting on October 12, 2026, to vote on a reverse stock split proposal aimed at regaining compliance with Nasdaq's minimum bid price requirement.

Summary

• Envoy Medical is convening a Special Meeting of Stockholders on October 12, 2026, to vote on a proposal to amend its Certificate of Incorporation.
• The primary purpose of the amendment is to authorize one or more reverse stock splits of its Class A Common Stock, with ratios ranging from 1-for-5 to 1-for-25, to be determined by the Board of Directors.
• This action is necessary to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share, which the company has failed to meet.
• The company received notices from Nasdaq regarding non-compliance on November 19, 2025, and May 18, 2026, and has been granted an extension until November 16, 2026, to comply.
• A second proposal concerns the adjournment of the meeting if necessary to solicit further proxies.
• Stockholders of record as of August 19, 2026, are eligible to vote.
• The reverse stock split is intended to increase the stock price, enhance liquidity, facilitate future financing, and attract investors, while avoiding penny stock status.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the company's precarious financial position necessitating a reverse stock split to avoid delisting, which often signals underlying business challenges.

Positives

• The company is taking proactive steps to address the minimum bid price deficiency and maintain its Nasdaq listing.
• A successful reverse stock split could potentially increase the stock price, improve marketability, and attract a broader range of investors.
• Maintaining the Nasdaq listing is crucial for future financing opportunities, including the ability to file shelf registration statements on Form S-3.

Negatives

• The company is at risk of delisting from the Nasdaq Capital Market if the reverse stock split is not approved or if it fails to regain compliance with the minimum bid price requirement by November 16, 2026.
• A reverse stock split can sometimes be viewed negatively by the market and may not guarantee a sustained increase in stock price or market capitalization.
• There is a risk that the reverse stock split could decrease the liquidity of the Class A Common Stock and lead to increased trading costs for stockholders holding odd lots.
• If delisted, the company would face significantly fewer opportunities to attract financing partners and would lose eligibility for Form S-3 shelf registration.

Risks

• Failure to regain compliance with Nasdaq's minimum bid price requirement by November 16, 2026, will lead to delisting.
• The reverse stock split may not be successful in increasing and maintaining the stock price above $1.00, potentially leading to further compliance issues or delisting.
• The reverse stock split could lead to a decrease in trading volume and liquidity, and may result in more stockholders holding odd lots, increasing transaction costs.
• If the company is delisted, its ability to raise capital will be severely hampered, impacting its business plans and operations, including obtaining FDA approval for its product candidate.
• There is a risk that the reverse stock split could be viewed negatively by the market, leading to a decrease in market capitalization.
• The company may face challenges in maintaining compliance with other Nasdaq listing rules, such as the requirement for a minimum number of round lot holders, following the reverse stock split.

Future Outlook

The company's immediate future outlook is heavily dependent on the outcome of the Special Meeting and its ability to regain compliance with Nasdaq's minimum bid price requirement. A successful reverse stock split is intended to improve stock price and liquidity, facilitating future financing and business operations. However, failure to comply could lead to delisting, significantly impacting the company's ability to execute its business plan and secure necessary capital.

Management Comments

• The Board believes the Reverse Stock Split Proposal will enable the Company to improve trading liquidity by increasing the price per share of our Class A Common Stock, which could enable a broader range of institutions to invest.
• The Board has determined that the amendment is advisable and in the best interests of the Company and its stockholders and has submitted the amendment for consideration by our stockholders at the Special Meeting.
• The Board believes that stockholder approval of a range of potential Reverse Stock Split ratios is in our best interests and stockholders because it is not possible to predict market conditions at the time the Reverse Stock Split would be implemented.

Industry Context

StockSavvy.ai notes that reverse stock splits are a common, albeit often controversial, tool used by companies struggling with low stock prices, particularly those listed on exchanges like Nasdaq that have minimum bid price requirements. This situation is not unique to Envoy Medical, as many smaller or growth-stage companies face similar challenges in maintaining exchange listing standards amidst market volatility or operational hurdles.

Stakeholder Impact

• Shareholders: May experience a reduction in the number of shares held, but their percentage ownership will remain the same unless fractional shares are cashed out. The primary concern is the potential impact on stock price and liquidity, and the risk of delisting.
• Creditors: Delisting could impair the company's ability to raise capital, potentially affecting its ability to meet financial obligations.
• Employees: Continued listing on Nasdaq is important for employee morale and the company's ability to attract and retain talent. Delisting could negatively impact future stock-based compensation value.
• Business Partners: Maintaining a Nasdaq listing enhances the company's credibility and stability, which is important for business partnerships and collaborations.

Next Steps

• Stockholders will vote on the Reverse Stock Split Proposal and the Adjournment Proposal at the Special Meeting on October 12, 2026.
• If approved, the Board of Directors will determine the specific ratio for the reverse stock split (between 1-for-5 and 1-for-25) and the effective date, which must be prior to December 31, 2026.
• The company must regain compliance with Nasdaq's minimum bid price requirement (stock price at or above $1.00 for at least 10 consecutive trading days) by November 16, 2026.
• If the reverse stock split is implemented, the company will file a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of Delaware.

Key Dates

Recommendation

The company is in a critical situation, facing potential delisting. While the reverse stock split is a necessary measure to maintain its listing and access to capital markets, it does not address underlying business performance issues. The outcome is uncertain, and the risks associated with delisting are significant. Therefore, a 'hold' recommendation is appropriate, pending further developments and clarity on the company's ability to achieve sustained compliance and operational success.

Keywords

Reverse Stock Split, Nasdaq Compliance, Minimum Bid Price, Stockholder Meeting, Class A Common Stock, Capital Markets, Liquidity, Delisting